Clinical Trial Update: Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating cabozantinib's effects on the bone immune microenvironment in bone-metastatic clear cell renal cell carcinoma (proof-of…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Cabometyx (cabozantinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Clear Cell Renal Cell Carcinoma | Phase 1 | Status: NOT_YET_RECRUITING